Journal of Antivirals & Antiretrovirals
Open Access

Emerging Antiviral Compounds for the Treatment of Chronic Hepatitis B and C

James Thompson^{* *}Correspondence: James Thompson, Department of Infectious Diseases, University of Manchester, Manchester, England, Email:

Author info »

Description

Chronic Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections remain significant global health challenges, affecting millions of people and leading to severe complications such as liver cirrhosis and hepatocellular carcinoma. Despite the availability of effective treatments, many patients do not achieve a Sustained Virologic Response (SVR) or experience treatment limitations due to side effects, resistance, or other factors. This has spurred intense research into emerging antiviral compounds that offer new hope for improved management and potential cures for these chronic infections.

Chronic hepatitis B is primarily treated with nucleotide analogs, such as tenofovir and entecavir, which effectively suppress viral replication. However, these therapies do not lead to complete viral eradication, necessitating lifelong treatment. Emerging compounds focus on novel mechanisms to achieve functional cures by targeting different aspects of the viral life cycle and enhancing the host's immune response. One promising class of drugs is the RNA interference (RNAi) therapeutics, which aim to reduce HBV RNA levels by silencing viral genes. For instance, therapies like JNJ-64179375 are designed to target HBV RNA, resulting in reduced viral replication and potentially allowing the host immune system to clear the infection. Early clinical trials have shown encouraging results, demonstrating significant reductions in viral load and improvements in liver function.

Another exciting avenue of research involves the use of immune modulators, such as therapeutic vaccines and Toll-Like Receptor (TLR) agonists, which enhance the body’s immune response to HBV. The TLR agonist, MGN1703, has shown promise in preclinical studies by activating innate and adaptive immunity, leading to a more robust attack on HBV-infected cells. The combination of these immunotherapeutic approaches with existing antiviral agents may provide a synergistic effect, facilitating viral clearance. Hepatitis C treatment has been revolutionized by the advent of Direct-Acting Antivirals (DAAs), which target specific steps in the viral life cycle. Current regimens are highly effective, achieving cure rates exceeding 95% in many populations. However, challenges remain, particularly for patients with genotypes resistant to existing therapies or those with liver damage.

Emerging antiviral compounds are being developed to expand treatment options for these difficult-to-treat populations. One promising class of drugs includes second-generation NS5A inhibitors, such as pibrentasvir and velpatasvir. These agents have shown potency against a wide range of HCV genotypes and exhibit a favorable resistance profile. Their use in combination with other DAAs, such as sofosbuvir, has resulted in highly effective, all oral regimens that can be administered over shorter durations, improving patient adherence. Furthermore, novel protease inhibitors like glecaprevir and voxilaprevir have emerged as key components in combination therapies. These drugs have been shown to maintain efficacy against resistant strains of HCV, providing viable treatment options for patients who have previously failed therapy. The flexibility of these combinations allows for tailored treatment strategies that can accommodate the unique characteristics of each patient’s infection.

A notable trend in the development of emerging antiviral compounds for both HBV and HCV is the pursuit of pangenotypic therapies. These treatments aim to provide a one-sizefits- all solution for multiple viral genotypes, reducing the complexity of treatment regimens and minimizing the need for extensive genotyping before therapy initiation. For hepatitis C, pan-genotypic regimens such as sofosbuvir/velpatasvir have already made significant impacts, simplifying treatment protocols and improving access to care. Similar strategies are being explored for hepatitis B, with the development of broadspectrum agents that can effectively target multiple HBV variants.

The complexity of chronic hepatitis infections calls for combination therapies that leverage multiple mechanisms of action. By combining existing antivirals with emerging compounds—such as immunomodulators, RNAi therapeutics, and novel small molecules—researchers aim to enhance treatment efficacy while reducing the risk of resistance. In the case of hepatitis B, ongoing studies are examining the potential of combining nucleotide analogs with immune-enhancing therapies to promote viral clearance and reduce reliance on lifelong treatment. Similarly, hepatitis C treatment is moving toward fixed-dose combinations that simplify regimens and enhance efficacy, paving the way for improved patient outcomes.

Conclusion

The landscape of antiviral treatment for chronic hepatitis B and C is evolving rapidly, driven by innovative research and the development of emerging compounds. As new therapies continue to emerge, the potential for functional cures becomes increasingly attainable. By focusing on combination strategies that incorporate diverse mechanisms of action, the medical community can enhance treatment efficacy, address the challenges of resistance, and improve patient adherence. The ongoing commitment to research and development in this field holds promise not only for those currently living with these infections but also for future generations. With continued advancements, we move closer to a world where chronic hepatitis B and C can be effectively managed or even cured, significantly reducing the burden of liver disease and improving global health outcomes.